Timothy Coughlin - May 1, 2025 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
Director
Signature
/s/ Nancy E. Denyes, as Attorney-in-Fact
Stock symbol
ATYR
Transactions as of
May 1, 2025
Transactions value $
$0
Form type
4
Date filed
5/2/2025, 05:16 PM
Previous filing
Jun 11, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
COUGHLIN TIMOTHY Director C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO /s/ Nancy E. Denyes, as Attorney-in-Fact 2025-05-02 0001376043

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATYR Stock Option (right to buy) Award $0 +50K $0.00 50K May 1, 2025 Common Stock 50K $3.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.